CTOs on the Move

Kriya Therapeutics

www.kriyatherapeutics.com

 
Kriya is a next-generation gene therapy company focused on designing and developing transformative new treatments for highly prevalent and severe chronic diseases.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Kriya Therapeutics raised $80.5M on 05/12/2020

Similar Companies

ReCode Therapeutics

ReCode Therapeutics is a biopharmaceutical company developing precision medicines for pulmonary diseases with significant unmet medical need.

Inimmune

Inimmue is a new biotechnology company founded by pharmaceutical industry veterans focused on developing next generation immunotherapeutics.

Sarepta Therapeutics

Sarepta Therapeutics is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Potenza Therapeutics

Potenza Therapeutics is a biotechnology company focused on building a diverse portfolio of oncology programs that utilize the body`s own immune system to seek out, recognize and destroy tumors through a diversity of mechanisms. Our programs are built upon novel biological insights into the tumor microenvironment and mechanisms by which cancer cells evade detection and destruction by the immune system. Potenza Therapeutics was founded in 2014 and is located in Cambridge, MA.

Vaxxas

Vaxxas is a privately held biotechnology company focused on enhancing the performance of existing and next-generation vaccines with its proprietary high-density microarray patch (HD-MAP). Vaxxas is targeting initial applications in infectious disease and oncology. In addition to HD-MAP HexaPro clinical studies of a COVID-19 vaccine patch, Vaxxas is performing demonstration work in preparation for clinical evaluation under contract with the United States Biomedical Advanced Research and Development Authority (BARDA) on pandemic vaccination solutions. Vaxxas core technology was initially developed at the University of Queensland. The company was founded with the completion of an initial equity financing led by OneVentures Innovation Fund I with co-investors Brandon Capital Partners, Brandon BioCatalyst, and US-based HealthCare Ventures, followed by a further financing led by OneVentures. OneVentures Innovation Fund I and Brandon BioCatalyst are supported by the Australian Government’s Innovation Investment Fund (IIF) program. The IIF is an Australian Government venture capital initiative that provides investment capital and managerial expertise through licensed venture capital fund managers to investee companies.